Vaxart (VXRT) Reports Publication of Peer-reviewed Journal Article Showing Potential Clinical & Economic Value of Norovirus Vaccine

Vaxart (VXRT) Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its SARS-CoV-2 Hamster Challenge Study, as well as a peer-reviewed publication in Nature Medicine resulting from a collaboration with prominent Stanford University scientists on COVID-19 vaccine candidates.

The latest data from the SARS-CoV-2 Hamster Challenge Study reinforces our belief that our oral COVID-19 vaccine candidate shows great promise. said Andrei Floroiu, chief executive officer of Vaxart. Our oral vaccine could help fight the COVID-19 epidemic... More